Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
20%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_2
6
50%
Ph phase_3
3
25%
Ph phase_4
3
25%

Phase Distribution

0

Early Stage

6

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
3(25.0%)
Phase 4Post-market surveillance
3(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (50.0%)
Phase 33 (25.0%)
Phase 43 (25.0%)

Trials by Status

terminated217%
completed1083%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
DRUG
Total Trials
12